TAmiRNA GmbH

We are thrilled to announce that TAmiRNA GmbH will participate in the SURGER-I Innsbruck Congress on December 12–13, 2024. This premier event brings together leading experts, researchers, and practitioners to explore advancements in hepatopancreatobiliary surgery and transplantation. As a proud sponsor, we will showcase our hepatomiR® kit, the first CE-IVD microRNA biomarker for the pre-operative assessment of liver function. Attendees can find us featured in the final program and on an intermission slide during the event. We are also delighted to share that Dr. Matthias Hackl, CEO/CSO of TAmiRNA, will be attending the conference. This provides an excellent opportunity to connect and learn about our latest clinical trial data, as well as how hepatomiR® can be implemented in clinical trials or routine diagnostics. We look forward to engaging with the vibrant community at SURGER-I Innsbruck 2024. Stay tuned for updates, and feel free to contact us at info@tamirna.com to arrange a meeting or discussion during the event. #hepatomiR #microRNA #biomarker #TAmiRNA

🚨Harness the Power of Transcriptomics in Biomarker Discovery 🚨 Join us for a live webinar on November 7th at 2 PM CET hosted by Biomedica Immunoassays! 👉 Register Now: https://lnkd.in/e66dYHr7 Title: Harnessing Transcriptomics: microRNA and mRNA Analysis for Biomarker Discovery, Basic Research, and Translational Applications 🔬 What to Expect: • Comprehensive Transcriptomics Sequencing Services tailored to your research needs • Insights into Biomarker Discovery, driving breakthrough advancements in diagnostics • Strategies to overcome challenges with low-input samples, including biofluids and extracellular vesicles • Opportunity to connect with our experts to discuss your transcriptomics goals and potential collaborations 📅 Date: 7.11.2024 🕒 Time: 14:00 -15:00 CET Presentation by Matthias Hackl, TAmiRNA GmbH – 40 minutes Q&A by Magdalena Mecking, TAmiRNA GmbH – 15 minutes Don’t miss this opportunity to advance your research with expert insights and practical solutions! #Transcriptomics #BiomarkerDiscovery #mRNA #microRNA #Diagnostics #Research

📢 Uncovering the potential of tRNAs as biomarkers in ESKD! We're excited to share the latest research of our collaborators, published in Thrombosis and Haemostasis, exploring the potential of tRNAs as biomarkers for thromboembolism and bleeding in end-stage kidney disease (ESKD) patients. The study aimed to identify small noncoding RNAs (sncRNAs) as novel biomarkers to predict thromboembolism and bleeding in patients with end-stage kidney disease (ESKD)—a population with a high risk for these complications. 🔍 Key Findings: - No significant differential expression of miRNAs was observed for either ischemic stroke or major bleeding. - Notably, four tRNAs were significantly differentially expressed in ischemic stroke cases, and seven in major bleeding cases (FDR<0.1), using our dedicated tRNA analysis workflow. 🔬 Conclusions and Implications: While miRNAs did not show differential expression, our findings underscore tRNAs as promising biomarkers for thromboembolic and bleeding risks in ESKD. This study paves the way for further research to refine the detection and prevention of life-threatening complications in ESKD patients. Stay tuned as we continue exploring innovative approaches to better understand and manage risks in high-need patient groups. Read the full study: https://lnkd.in/eVey7Y5h #Biomarker #ESKD #RNAseq #Thromboembolism #Hemodialysis #PrecisionMedicine #tRNAs

Great to connect with so many brilliant minds at the EV Forum last week! Thanks to the organizers Precision Medicine Forum for a fantastic event.

Don't miss out on our webinar together with Biomedica Immunoassays!

🌟 Advancing EV Characterization and Therapeutics at the Precision EV Forum! 🌟 Excited to share that TAmiRNA GmbH and Evercyte GmbH will join forces at the upcoming Precision EV Forum in Cambridge! 🚀 As key members of the EVscale® consortium, they’ll be showcasing cutting-edge solutions in EV (#extracellularvesicles) characterization and production. - Evercyte GmbH's Clinical-Grade EVs: Harnessing the potential of telomerized MSC-derived EVs for therapeutic applications. - Phoenestra GmbH's Bioreactor Technology: Enabling faster, scalable EV production. - TAmiRNA GmbH's Advanced Multiomic Capabilities: Unlocking the power of RNA cargo analysis for biomarker discovery and therapeutics development. Catch us at Cripps Court Conference Centre! 💡🔬 #PrecisionMedicine #EVscale #Biomarkers #Therapeutics #Biotech #Innovation #TAmiRNA #Evercyte #EVForum

🌟 New Publication Alert! 🌟 Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated #miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of miRNAs such as mmu-miR-466i-5p and mmu-miR-1195 in both serum and bone marrow of diabetic mice. Dysregulated miRNAs were linked to pathways associated with diabetes-related signaling and diabetic bone disease, shedding light on potential mechanistic pathways. Cell-type enrichment analysis pointed towards miRNAs enriched in specific cell types like immune cells, hepatocytes, and mesenchymal stem cells, which could hold the key to understanding T2DM-induced bone fragility. This study emphasizes the power of miRNAs as #biomarkers for diseases like T2DM, offering new perspectives on diabetic bone disease. 🔗 Read the full study [https://lnkd.in/gvwdezUe]. #Type2Diabetes #BoneFragility #miRNA #Genomics #ComputationalBiology #Biomarkers #T2DM #ScientificResearch #DiabeticBoneDisease #Biology #PrecisionMedicine #BoneHealth

🎉 Celebrating the Nobel Prize in Physiology or Medicine 2024! 🎉 Congratulations to Victor Ambros and Gary Ruvkun, this year’s Nobel Laureates, for their pioneering discovery of microRNAs—tiny but powerful molecules that regulate gene expression and have reshaped our understanding of biology, aging, cancer, and development. At TAmiRNA GmbH, we’ve been deeply inspired by this breakthrough and have dedicated over 10 years to harnessing the potential of microRNAs. We’ve developed cutting-edge diagnostic tools that leverage microRNAs as biomarkers, with our regulatory approved hepatomiR® device leading the way in improving liver cancer patient care across Europe. Our passion for innovation has resulted in over 100 scientific publications, and we’re proud to contribute to advancing this transformative field. The Nobel Prize serves as a reminder of the impact that these discoveries can have on medical technologies, and we’re committed to pushing the boundaries further—developing novel diagnostic and therapeutic solutions based on this incredible science. 🔬 Let’s continue to drive innovation in healthcare together! #NobelPrize #microRNA #Innovation #TAmiRNA #MedicalTechnology #Biotech #CancerResearch #LiverCancer #Diagnostics

🌟 Exciting News from TAmiRNA GmbH at the GSEV 2024 Scientific Conference! We are thrilled to announce that TAmiRNA will contribute a poster at the upcoming German Society for Extracellular Vesicles (GSEV) Autumn Meeting 2024, presenting our recent advancements in the biodistribution of extracellular vesicles (EVs). The poster will be presented by our expert, Magdalena Mecking. 💡 Highlighting Our Cutting-Edge EV Characterization Services 💡 TAmiRNA will also use the conference’s networking sessions to introduce our unique EV characterization services. These services are designed for academic and industry researchers exploring the use of EVs as biomarkers or therapies. With a special focus on transcriptomic analysis of small and large RNAs, powered by our NextGen sequencing miND® platform, we offer advanced multiomics capabilities to help accelerate discoveries. 🔗 Learn more about our innovative work at www.tamirna.com. https://lnkd.in/df4YViUJ   #ExtracellularVesicles #EVResearch #Transcriptomics #miRNA #Biomarkers #GSEV2024 #NextGenSequencing #TAmiRNA #InnovationInBiotech

🚀 Exciting news! A new study from the Università degli Studi di Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. 🔬 This research, leveraging TAmiRNA GmbH's Next-Generation Sequencing (NGS)-based #miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. 💡 This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific #EVs and their miRNA cargo. Read the full study: https://lnkd.in/d2QKBTND #miRNA #EVs #TAmiRNA #biomarkers #NGS #ClinicalPharmacology #TranslationalScience #PediatricMedicine